Biocon's Breakthrough: Yesafili Gets Green Light in Canada

Biocon's Breakthrough: Yesafili Gets Green Light in Canada

Biocon Biologics has received Health Canada's approval for Yesafili, a biosimilar injection for eye ailments. As the first Eylea biosimilar approved in Canada, Yesafili's launch is set for July 4, 2025. This milestone highlights Biocon's commitment to affordable, high-quality biologics worldwide.

Biocon Biologics gets Health Canada approval for its AMD biosimilar Yesafili

The Indian drug is the first biosimilar to US biotech giant Regeneron Pharma's Eylea approved in Canada.

Biocon Biologics gets nod to launch eye medicine, Yesafili in Canada

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea in Canada, with a global launch scheduled for July 4, 2025, targeting treatment of serious eye diseases.

Biocon Biologics Receives Health Canada Approval for Yesafili™ (aflibercept); First Global Launch Scheduled for July 2025

TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a fully integrated global...

Health Canada approves Biocon Biologics’ YESAFILI, first EYLEA biosimilar, for launch in July 2025 - Express Pharma

Biocon Biologics (BBL), a biosimilars company and subsidiary of Biocon, has announced that Health Canada has granted a Notice of Compliance (NOC) for YESAFILI (aflibercept), a biosimilar to EYLEA (aflibercept) injection. The approval covers vial and prefilled syringe presentations, 2 mg/0.05 mL, and was granted on 26 June 2025. The company has scheduled the product’s Canadian launch for 4 July 2025. YESAFILI is the first biosimilar to EYLEA to b…

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

Regulators and manufacturers advance biosimilars for aflibercept, omalizumab, and dupilumab, enhancing access to treatment in Europe and Latin America.